Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skeletal muscle-derived cell implantation for fecal incontinence (FI-3)
jRCT2033230027Phase 3Recruiting
- Sponsor
- Innovacell
- Start
- Oct 2022
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Phase 3, randomised, double-blind trial of ICEF 15 in fecal incontinence (FI) (2 arms), sponsored by Innovacell. Primary endpoint: Primary: Change in frequency of urge fecal incontinence episodes at 12 months. Started Oct 2022; status: recruiting.
02
Drugs
ICEF 15
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on jRCT2033230027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230027.